A Phase 2/3 interventional study of Liquid Rotavirus Vaccine in Rotavirus Gastroenteritis, sponsored by Serum Institute of India Pvt. Ltd.. Completed at 8 sites in India. Open to participants aged 6 Weeks to 8 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-09-10.
Sponsored by Serum Institute of India Pvt. Ltd. · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Gastroenteritis with a site in India — none open to participants now, none under way, none of them phase 3. Gastroenteritis · India.
Among the 12 studies in Gastroenteritis with a site in India, this one is the only one that started in 2017, is one of 2 in phase 2/3, and was the 12th registered.
237 studies on the registry are indexed under Gastroenteritis; 16 are open to participants now.
Browse Gastroenteritis studies →None of the 12 studies in Gastroenteritis with a site in India is open now. The open studies under Gastroenteritis, anywhere →
Of the 13 Gastroenteritis studies recruiting now, 5 (38%) set no upper age limit and 8 (62%) stop at 75 or younger; 11 take children under 18; 3 take healthy volunteers.
This study: 6 Weeks to 8 Weeks · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 6
First in 2007; this study’s year is marked. 1 started in 2017.
This study's enrollment of 1,500 is above the median of 136 across 164 interventional studies indexed under Gastroenteritis.
Median enrollment 330 across the 9 interventional studies, 266 across the 2 observational. Of the 10 that completed or were terminated, 1 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 12 have an industry lead sponsor. The 8 most frequent:
Serum Institute of India Pvt. Ltd. is the lead sponsor of 26 studies on the registry; 6 are open to participants now.
Serum Institute of India Pvt. Ltd. has 3 studies filed under Gastroenteritis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Gastroenteritis with a site in India, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study has been designed to compare the liquid formulation of BRV-PV (LBRV-PV) with the lyophilized formulation (ROTASIIL) by testing the vaccine in infants (three doses administered 4 weeks apart, starting at 6-8 weeks of age) in order to demonstrate the non-inferiority in the induction of specific anti-rotavirus IgA antibodies by these vaccines. The study will also evaluate lot-to-lot consistency in the manufacture of LBRV-PV by demonstrating equivalence in the induction of specific anti-rotavirus IgA antibodies across three production lots.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study participants in this arm will receive one of the three liquid rotavirus vaccine lots (LBRV-PV Lot A).
Biological: Liquid Rotavirus Vaccine
The study participants in this arm will receive one of the three liquid rotavirus vaccine lots (LBRV-PV Lot B).
Biological: Liquid Rotavirus Vaccine
The study participants in this arm will receive one of the three liquid rotavirus vaccine lots (LBRV-PV Lot C).
Biological: Liquid Rotavirus Vaccine
The study participants in this arm will receive ROTASIIL, the licensed lyophilized rotavirus vaccine in India.
Biological: Liquid Rotavirus Vaccine
Liquid Rotavirus Vaccine and Lyophilized Rotavirus Vaccine
Also known as: ROTASIIL
Immunogenicity of rotavirus vaccine
Serum anti- rotavirus IgA antibody concentrations expressed as GMCs for the comparison of LBRV-PV vaccine and ROTASIIL
Time frame: 28 days post dose 3
Immunogenicity Endpoints
GMCs of serum anti- rotavirus IgA antibody among the LBRV-PV lots at four weeks after the third vaccination.
Time frame: 28 days post dose 3
Immunogenicity Endpoints
Proportion of subjects achieving IgA antibody concentration ≥20 U/ml for the comparison of LBRV-PV and ROTASIIL.
Time frame: 28 days post dose 3
Plan to share: No
Ran from Oct 2017 to primary completion in Jun 2018, 7 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Serum Institute of India Pvt. Ltd. →